SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-000731
Filing Date
2023-01-13
Accepted
2023-01-13 08:35:26
Documents
13
Period of Report
2023-01-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K labp-20230110.htm   iXBRL 8-K 57367
2 EX-10.1 labp-ex10_1.htm EX-10.1 54205
  Complete submission text file 0000950170-23-000731.txt   233969

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20230110.xsd EX-101.SCH 2478
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20230110_pre.xml EX-101.PRE 9846
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20230110_lab.xml EX-101.LAB 13350
7 EXTRACTED XBRL INSTANCE DOCUMENT labp-20230110_htm.xml XML 4696
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 23527344
SIC: 2834 Pharmaceutical Preparations